Thiazolyl-pyrazolo[1,5-a]pyrimidine Synthesis via Copper Halide Catalysis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current synthetic methods for thiazolyl-pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists are economically inefficient and often use mutagenic and environmentally toxic catalysts, limiting yield and process safety.

Innovation Solution

A novel synthetic process using copper halide catalysts, specific ligands like 1,10-phenanthroline, and bases such as K3PO4 and Cs2CO3, in conjunction with morpholine, to efficiently produce thiazolyl-pyrazolo[1,5-a]pyrimidine compounds, avoiding the use of harmful materials and improving yield.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of manufacture

If conventional synthetic methods are used to produce thiazolyl-pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists, then the compounds can be synthesized, but the process is economically inefficient and uses mutagenic and environmentally toxic catalysts

Engineering Contradiction:

Improveeconomic efficiencyVSAvoidtoxic catalysts

Core Design Contradiction:

Ease of manufactureVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical parameters of the catalytic system by switching from conventional toxic catalysts to copper halide catalysts (CuI, CuBr, CuCl) combined with specific ligands (1,10-phenanthroline, bipyridine). This parameter change maintains catalytic activity while eliminating mutagenic and environmentally toxic materials, thereby improving economic efficiency and reducing harmful factors.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces ligand intermediaries (1,10-phenanthroline and bipyridine) that mediate between the copper halide catalyst and the substrate. These ligands facilitate the catalytic cycle, enabling efficient synthesis without requiring toxic catalysts, thus resolving the contradiction between ease of manufacture and harmful factors.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If conventional synthetic methods are used, then the compounds can be synthesized, but the yield is limited

Engineering Contradiction:

ImproveyieldVSAvoidsynthetic efficiency

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent optimizes reaction parameters by changing the catalyst system to copper halides with specific ligands and adjusting base choices (K3PO4, Cs2CO3). These parameter changes result in higher yields and improved synthetic efficiency, directly addressing the limitation of conventional methods.

Inventive Principle:

Principle #35Parameter changes

3Ease of manufacture

If conventional synthetic methods are used, then the compounds can be synthesized, but the process uses mutagenic materials

Engineering Contradiction:

Improvesynthetic capabilityVSAvoidmutagenic materials

Core Design Contradiction:

Ease of manufactureVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful mutagenic catalysts of conventional methods into beneficial copper halide catalysts with ligands. This substitution maintains the synthetic capability while eliminating mutagenic materials, turning a harmful process into a safe and efficient one.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process achieves higher yields and economic efficiency while minimizing the use of toxic materials, resulting in high-purity thiazolyl-pyrazolo[1,5-a]pyrimidine compounds suitable as CRF-1 receptor antagonists for psychiatric and neuroendocrine disorder treatments.

Implementation Method 1

reacting a compound of Formula III, or a salt thereof, with 2,4-di-chlorothiazole, or a salt thereof, in the presence of a copper halide catalyst

Methodology Applied

Scientific EffectCatalysis: Catalysis

Implementation Method 2

reacting a compound of Formula III, or a salt thereof, with 2,4-di-chlorothiazole, or a salt thereof, in the presence of a copper halide catalyst, a ligand selected from 1,10-phenanthroline and bipyridine, and a base selected from K3PO4 and Cs2CO3

Methodology Applied

Scientific EffectBase-catalyzed nucleophilic substitution: